切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2017, Vol. 11 ›› Issue (15) : 2097 -2100. doi: 10.3877/cma.j.issn.1674-0785.2017.15.008

所属专题: 文献

综述

米氮平在精神药物不良反应中的应用进展
于相芬1, 孙宇新2, 孙振晓1,()   
  1. 1. 276005 临沂市精神卫生中心精神科
    2. 250012 济南,山东大学医学院2013级
  • 收稿日期:2017-02-16 出版日期:2017-08-01
  • 通信作者: 孙振晓

Application of mirtazapine in management of side effects of psychotropic drugs

Xiangfen Yu1, Yuxin Sun2, Zhenxiao Sun1,()   

  1. 1. Department of Psychiatry, Linyi Municipal Mental Health Center, Linyi 276005, China
    2. 2013 Grade of Medical College of Shandong University, Jinan 250012, China
  • Received:2017-02-16 Published:2017-08-01
  • Corresponding author: Zhenxiao Sun
  • About author:
    Corresponding author: Sun Zhenxiao, Email:
引用本文:

于相芬, 孙宇新, 孙振晓. 米氮平在精神药物不良反应中的应用进展[J]. 中华临床医师杂志(电子版), 2017, 11(15): 2097-2100.

Xiangfen Yu, Yuxin Sun, Zhenxiao Sun. Application of mirtazapine in management of side effects of psychotropic drugs[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(15): 2097-2100.

米氮平(Mirtazapine)是一种去甲肾上腺素(NE)和特异性5-羟色胺(5-HT)能抗抑郁剂,近年来,被应用于多种精神药物不良反应的治疗。本文对米氮平在抗精神病药物所致静坐不能、选择性5-HT再摄取抑制剂所致抗利尿激素不适当分泌综合征、多汗症、恶心、呕吐、尿潴留、帕罗西汀所致高催乳素血症乳溢、精神药物所致性功能障碍、氯氮平所致流涎、协助苯二氮类药物戒断中的应用情况作一综述。

Mirtazapine is a noradrenergic and specific serotonergic antidepressant, and it has been used to manage the side effects of many psychotropic drugs. This paper reviews the application of mirtazapine in the management of antipsychotic-induced akathisia, selective serotonin reuptake inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone, hyperhidrosis, nausea, vomiting, urinary retention, paroxetine-induced hyper-prolactinemic galactorrhoea, psychotropic drug-induced sexual dysfunction, and clozapine-induced sialorrhea, as well as in aiding benzodiazepine withdrawal.

[1]
孙振晓,于相芬,孙波. 米氮平的临床应用及其不良反应 [J]. 精神医学杂志, 2012, 25(4):310-313.
[2]
Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem [J]. Br J Psychiatry, 2001, 179(1):4-8.
[3]
于相芬,孙振晓,孙波. 抗精神病药物所致急性静坐不能的研究现状 [J]. 中国执业药师, 2012, 9(4):32-38.
[4]
Poyurovsky M. Acute antipsychotic-induced akathisia revisited [J]. Br J Psychaitry, 2010, 196(2):89-91.
[5]
Poyurovsky M, Weizman A. Mirtazapine for neuroleptic-induced akathisia [J]. Am J Psychiatry, 2001, 158(5):819.
[6]
Poyurovsky M, Bergman J, Pashinian A, et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia [J]. Int Clin Psychopharmacol, 2014, 29(5):296-298.
[7]
Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia [J]. Ann Pharmacother, 2008, 42(6):841-846.
[8]
Praharaj SK, Kongasseri S, Behere RV, et al. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials [J]. Ther Adv Psychopharmacol, 2015, 5(5):307-313.
[9]
Koufakis T. Quetiapine-induced syndrome of inappropriate secretion of antidiuretic hormone [J]. Case Rep Psychiatry, 2016, 2016:4803132.
[10]
Jagsch C, Marksteiner J, Seiringer E, et al. Successful mirtazapine treatment of an 81-year-old patient with syndrome of inappropriate antidiuretic hormone secretion [J]. Pharmacopsychiatry, 2007, 40(3):129-131.
[11]
Mogi T, Yoshino A, Ikemoto G, et al. Mirtazapine as an alternative for selective-serotonin-reuptake-inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone [J]. Psychiatry Clin Neurosci, 2012, 66(1):80.
[12]
孙振晓,于相芬. 抗抑郁剂所致多汗症的研究现状 [J]. 中国执业药师, 2013, 10(12):23-25, 38.
[13]
Buecking A, Vandeleur CL, Khazaal Y, et al. Mirtazapine in drug-induced excessive sweating [J]. Eur J Clin Pharmacol, 2005, 61(7):543-544.
[14]
Edwards JG, Anderson I. Systematic review and guide to selelection of selective serotonin reuptake inhibitors [J]. Drugs, 1999, 57(4):507-533.
[15]
Caldis EV, Gair RD. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors [J]. Can J Psychiatry, 2004, 49(10):707.
[16]
喻东山,葛茂宏,苏海陵. 精神科合理用药手册[M]. 3版. 南京: 江苏凤凰科学技术出版社, 2016: 270.
[17]
Lenze EJ. Reversal of SSRI-associated urinary retention with mirtazapine augmentation [J]. J Clin Psychopharmacol, 2012, 32(3):434.
[18]
Chatterjee SS, Mitra S, Mallik N. Emerging hyperprolactinemic galactorrhea in obsessive compulsive disorder with a stable dose of Fluoxetine [J]. Clin Psychopharmacol Neurosci, 2015, 13(3):316-318.
[19]
Stahl S. Stahl′s essential psychopharmacology: neuroscientific basis and practical application [M]. 4th ed. Cambridge: Cambridge University Press, 2013: 298-318.
[20]
Singh M, Anwar Z, Sinha V, et al. Mirtazapine in Paroxetine Induced Hyper-prolactinemic Galactorrhoea [J]. Clin Psychopharmacol Neurosci, 2015, 13(2):222-223.
[21]
Fava M, Rankin M. Sexual functioning and SSRIs [J]. J Clin Psychiatry, 2002, 63(S5):25-30.
[22]
Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer anti- depressants [J]. J Clin Psychiatry, 2002, 63(4):357-366.
[23]
Khawam EA, Laurencic G, Malone JR. Side effects of antidepressants: An overview [J]. Cleveland Clin J Med, 2006, 73(4):351-361.
[24]
Atmaca M, Korkmaz S, Topuz M, et al. Mirtazapine augmentation for selective serotonin reuptake inhibitor-induced sexual dysfunction: a retropective investigation [J]. Psychiatry Investig, 2011, 8(1):55-57.
[25]
Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction [J]. J Clin Psychiatry, 2000, 61(5):356-360.
[26]
Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors [J]. Hum Psychopharmacol, 2008, 23(4):321-326.
[27]
Terevnikov V, Stenberg JH, Tiihonen J, et al. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics [J]. Nord J Psychiatry, 2017, 71(1):77-80.
[28]
Glick AR, Khan IA, Sher L. Treatment of antipsychotic-induced sialorrhea [J]. Psychiat Ann, 2014, 44(6):267-269.
[29]
张荣华,季建林. 苯二氮卓类药物的依赖及戒断 [J]. 国外医学(精神病学分册), 2005, 32(2):82-85.
[30]
Chandrasekaran PK. Employing mirtazapine to aid benzodiazepine withdrawal [J]. Singapore Med J, 2008, 49(6):e166-167.
[1] 张永博, 张亮, 陈浏阳, 戴睿, 孙华, 杨盛, 孟博, 彭晴. 线粒体与椎间盘退变[J]. 中华损伤与修复杂志(电子版), 2023, 18(03): 265-269.
[2] 樊逸隽, 杨枫, 王玮, 殷鹤英, 刘俊. 喉前淋巴结转移对甲状腺乳头状癌诊疗价值的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 306-310.
[3] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[4] 汪沛, 倪蓓君, 元及, 宫为一, 范军. 卡瑞利珠单抗联合卡铂和培美曲塞治疗进展期肺腺癌的疗效及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 511-513.
[5] 张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[6] 李丹阳, 李满祥. 肠道菌群失调在肺动脉高压发病中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 432-434.
[7] 张灵, 杨荀, 蒋水平, 李小华. 老年慢性阻塞性肺疾病诊断与治疗新进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 285-289.
[8] 龙慧玲, 林蜜, 邵婷. 三维球体间充质干细胞培养技术的研究进展及其应用[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 229-234.
[9] 秦富豪, 郑正, 江滨. 间充质干细胞在克罗恩病肛瘘治疗中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 172-177.
[10] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[11] 侍新宇, 孙金兵, 何宋兵. 血液生物标志物在直肠癌新辅助治疗中的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(03): 228-233.
[12] 任加发, 邬步云, 邢昌赢, 毛慧娟. 2022年急性肾损伤领域基础与临床研究进展[J]. 中华肾病研究电子杂志, 2023, 12(05): 276-281.
[13] 何佳伟, 张良, 杨骐, 王占祥. 创伤性颅脑损伤后进展性出血性损伤的诊疗现状[J]. 中华神经创伤外科电子杂志, 2023, 09(03): 175-179.
[14] 张坤淇, 张睿, 徐佳, 康庆林. 漂浮膝损伤的诊治进展[J]. 中华老年骨科与康复电子杂志, 2023, 09(04): 252-256.
[15] 吴一菡, 雷章, 卢宏达. MUC16/CA125在良恶性肿瘤诊治中的作用及其研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 591-595.
阅读次数
全文


摘要